Safety and efficacy of an α 1 -blocker plus mirabegron compared with an α 1 -blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: a systematic review and network meta-analysis.

Sender Herschorn Tufan TarcanYuan-Hong JiangEric ChungFarid Abdul HadiAchim SteupBudiwan Sumarsono

Published in: Neurourology and urodynamics (2024)

-blocker plus antimuscarinic have similar safety and efficacy profiles in male patients with LUTS secondary to BPH and OAB. Patients may, therefore, benefit from the use of either combination within the clinical setting.

Keyphrases

lower urinary tract symptoms
benign prostatic hyperplasia
end stage renal disease
ejection fraction
newly diagnosed
angiotensin converting enzyme
chronic kidney disease
middle aged